Treatment of adrenal crisis in patients with primary hypoadrenalism can lead to hypertension

• Published in: Clinical Pediatric Endocrinology Vol. 28; no. 2; pp. 25 - 30
• Main Authors: Fusa Nagamatsu, Satoko Satoh, Yasuko Ogiwara, Kazuhiro Shimura, Aya Shimada, Rumi Hachiya, Yukihiro Hasegawa
• Format: Journal Article
• Language: Japanese
• Published: The Japanese Society for Pediatric Endocrinology 01.04.2019
• ISSN: 0918-5739; 1347-7358

[Abstract.] Hypertension is one of the most serious side effects of glucocorticoid therapy. We retrospectively investigated the frequency of hypertension during treatment of adrenal crisis and analyzed the factors associated with its development. Patients who were admitted for primary hypoadrenalism due to diagnosed or suspected adrenal crisis were included. In the analysis, the subjects were divided into two groups: the hypertensive group (group H) and non-hypertensive group (group Non-H). The primary endpoint was the difference in the hourly therapeutic hydrocortisone (HDC) dosage between the two groups. The hourly therapeutic HDC dose in the two groups was defined as the hourly HDC dose from the start of HDC infusion until the development of hypertension in group H or until the last blood pressure measurement in group Non-H. Nine of 19 crises led to hypertension. There was no significant difference in the therapeutic HDC dosage between the groups (p=0.108). In conclusion, hypertension developed in some patients during treatment for adrenal crisis. There was no significant difference in the therapeutic HDC dosage between groups H and Non-H.